Bupropion induced serotonin syndrome: a case report. 2010

Elizabeth L Thorpe, and Anthony F Pizon, and Michael J Lynch, and Jessica Boyer
Department of Pediatrics, Division of Emergency Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.

Although there are no documented cases of serotonin syndrome (SS) following bupropion ingestion alone in the literature, the ability of bupropion to potentiate serotonin levels and lead to SS is known. A 15-year-old boy was found at home hallucinating. He then developed tonic-clonic activity. Upon arrival in the emergency department, he was confused and restless. On exam, he had tachycardia, hypertension, dilated pupils and dry oral mucosa, normal tone and reflexes in his arms, but rigidity and +4 reflexes in his legs with sustained clonus at his ankles. He was admitted and treated with intravenous fluids and lorazepam for his agitation. A urine drug screen (via gas chromatography/mass spectrometry) was positive only for naproxen and bupropion. Serum bupropion and hydroxybupropion levels drawn 17 h after his reported ingestion were 280 (therapeutic range 50-100) and 3,100 ng/mL (therapeutic range <485), respectively. Within 24 h of his admission, the patient was awake with normal vital signs and neurologic exam. To our knowledge, there are only three reported cases demonstrating SS in conjunction with bupropion toxicity; however, none of these were secondary to bupropion alone.

UI MeSH Term Description Entries
D008297 Male Males
D008401 Gas Chromatography-Mass Spectrometry A microanalytical technique combining mass spectrometry and gas chromatography for the qualitative as well as quantitative determinations of compounds. Chromatography, Gas-Liquid-Mass Spectrometry,Chromatography, Gas-Mass Spectrometry,GCMS,Spectrometry, Mass-Gas Chromatography,Spectrum Analysis, Mass-Gas Chromatography,Gas-Liquid Chromatography-Mass Spectrometry,Mass Spectrometry-Gas Chromatography,Chromatography, Gas Liquid Mass Spectrometry,Chromatography, Gas Mass Spectrometry,Chromatography, Mass Spectrometry-Gas,Chromatography-Mass Spectrometry, Gas,Chromatography-Mass Spectrometry, Gas-Liquid,Gas Chromatography Mass Spectrometry,Gas Liquid Chromatography Mass Spectrometry,Mass Spectrometry Gas Chromatography,Spectrometries, Mass-Gas Chromatography,Spectrometry, Gas Chromatography-Mass,Spectrometry, Gas-Liquid Chromatography-Mass,Spectrometry, Mass Gas Chromatography,Spectrometry-Gas Chromatography, Mass,Spectrum Analysis, Mass Gas Chromatography
D011595 Psychomotor Agitation A feeling of restlessness associated with increased motor activity. This may occur as a manifestation of nervous system drug toxicity or other conditions. Agitation, Psychomotor,Akathisia,Excitement, Psychomotor,Restlessness,Psychomotor Hyperactivity,Psychomotor Restlessness,Hyperactivity, Psychomotor,Psychomotor Excitement,Restlessness, Psychomotor
D011605 Psychoses, Substance-Induced Psychotic organic mental disorders resulting from the toxic effect of drugs and chemicals or other harmful substance. Psychoses, Drug,Psychoses, Toxic,Substance-Induced Psychoses,Toxic Psychoses,Drug Psychoses,Psychoses, Substance Induced,Substance Induced Psychoses
D003692 Delayed-Action Preparations Dosage forms of a drug that act over a period of time by controlled-release processes or technology. Controlled Release Formulation,Controlled-Release Formulation,Controlled-Release Preparation,Delayed-Action Preparation,Depot Preparation,Depot Preparations,Extended Release Formulation,Extended Release Preparation,Prolonged-Action Preparation,Prolonged-Action Preparations,Sustained Release Formulation,Sustained-Release Preparation,Sustained-Release Preparations,Timed-Release Preparation,Timed-Release Preparations,Controlled-Release Formulations,Controlled-Release Preparations,Extended Release Formulations,Extended Release Preparations,Slow Release Formulation,Sustained Release Formulations,Controlled Release Formulations,Controlled Release Preparation,Controlled Release Preparations,Delayed Action Preparation,Delayed Action Preparations,Formulation, Controlled Release,Formulations, Controlled Release,Prolonged Action Preparation,Release Formulation, Controlled,Release Formulations, Controlled,Sustained Release Preparation,Timed Release Preparation,Timed Release Preparations
D003693 Delirium A disorder characterized by CONFUSION; inattentiveness; disorientation; ILLUSIONS; HALLUCINATIONS; agitation; and in some instances autonomic nervous system overactivity. It may result from toxic/metabolic conditions or structural brain lesions. (From Adams et al., Principles of Neurology, 6th ed, pp411-2) Delirium of Mixed Origin,Subacute Delirium,Delirium, Subacute,Deliriums, Subacute,Mixed Origin Delirium,Mixed Origin Deliriums,Subacute Deliriums
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D016642 Bupropion A propiophenone-derived antidepressant and antismoking agent that inhibits the uptake of DOPAMINE. (+-)-1-(3-Chlorophenyl)-2-((1,1-dimethylethyl)amino)-1-propanone,Amfebutamone,Bupropion Hydrochloride,Bupropion Hydrochloride, (+-)-Isomer,Bupropion, (+-)-Isomer,Quomen,Wellbutrin,Zyban (Anti-Smoking),Zyban (Bupropion),Zyntabac
D018765 Dopamine Uptake Inhibitors Drugs that block the transport of DOPAMINE into axon terminals or into storage vesicles within terminals. Most of the ADRENERGIC UPTAKE INHIBITORS also inhibit dopamine uptake. Dopamine Reuptake Inhibitors,Inhibitors, Dopamine Reuptake,Inhibitors, Dopamine Uptake,Reuptake Inhibitors, Dopamine,Uptake Inhibitors, Dopamine

Related Publications

Elizabeth L Thorpe, and Anthony F Pizon, and Michael J Lynch, and Jessica Boyer
July 2005, The Kaohsiung journal of medical sciences,
Elizabeth L Thorpe, and Anthony F Pizon, and Michael J Lynch, and Jessica Boyer
October 2022, Cureus,
Elizabeth L Thorpe, and Anthony F Pizon, and Michael J Lynch, and Jessica Boyer
January 2004, Clinical neuropharmacology,
Elizabeth L Thorpe, and Anthony F Pizon, and Michael J Lynch, and Jessica Boyer
January 2007, Primary care companion to the Journal of clinical psychiatry,
Elizabeth L Thorpe, and Anthony F Pizon, and Michael J Lynch, and Jessica Boyer
January 2015, Clinical neuropharmacology,
Elizabeth L Thorpe, and Anthony F Pizon, and Michael J Lynch, and Jessica Boyer
August 2009, Journal of clinical pharmacy and therapeutics,
Elizabeth L Thorpe, and Anthony F Pizon, and Michael J Lynch, and Jessica Boyer
July 2005, Journal of the Medical Association of Thailand = Chotmaihet thangphaet,
Elizabeth L Thorpe, and Anthony F Pizon, and Michael J Lynch, and Jessica Boyer
January 1986, Journal of clinical pharmacology,
Elizabeth L Thorpe, and Anthony F Pizon, and Michael J Lynch, and Jessica Boyer
April 2006, Movement disorders : official journal of the Movement Disorder Society,
Elizabeth L Thorpe, and Anthony F Pizon, and Michael J Lynch, and Jessica Boyer
January 2015, Clinical neuropharmacology,
Copied contents to your clipboard!